Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Tarsus Pharmaceuticals has received a consensus recommendation of "Moderate Buy" from analysts, with five out of eight brokerages assigning a buy rating and an average price objective of $66.67.
• Insider trading activity includes CEO Bobak R. Azamian selling 6,000 shares for approximately $332,220, while director William J. Phd Link sold 27,116 shares worth about $1.55 million.
• In the latest earnings report, Tarsus Pharmaceuticals posted a loss of ($0.48) earnings per share, missing estimates, but achieved revenue of $102.66 million, exceeding expectations.

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eight brokerages that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $66.6667.

Several research analysts have weighed in on the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Tarsus Pharmaceuticals in a research report on Wednesday, October 8th. Zacks Research raised shares of Tarsus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Friday, September 5th.

Insider Buying and Selling

In related news, CEO Bobak R. Azamian sold 6,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 24th. The stock was sold at an average price of $55.37, for a total value of $332,220.00. Following the transaction, the chief executive officer directly owned 812,106 shares of the company's stock, valued at approximately $44,966,309.22. This trade represents a 0.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director William J. Phd Link sold 27,116 shares of the stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $57.00, for a total value of $1,545,612.00. Following the transaction, the director owned 143,332 shares in the company, valued at approximately $8,169,924. This trade represents a 15.91% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 39,116 shares of company stock worth $2,177,832 over the last three months. 8.97% of the stock is owned by company insiders.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Paradigm Biocapital Advisors LP increased its stake in shares of Tarsus Pharmaceuticals by 3.1% in the first quarter. Paradigm Biocapital Advisors LP now owns 2,610,197 shares of the company's stock worth $134,086,000 after purchasing an additional 78,301 shares during the period. Vanguard Group Inc. grew its holdings in Tarsus Pharmaceuticals by 5.3% in the 1st quarter. Vanguard Group Inc. now owns 2,226,595 shares of the company's stock valued at $114,380,000 after buying an additional 111,433 shares during the last quarter. Lord Abbett & CO. LLC grew its holdings in Tarsus Pharmaceuticals by 4.0% in the 1st quarter. Lord Abbett & CO. LLC now owns 1,331,701 shares of the company's stock valued at $68,409,000 after buying an additional 51,714 shares during the last quarter. Assenagon Asset Management S.A. increased its position in Tarsus Pharmaceuticals by 25.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,247,954 shares of the company's stock worth $74,166,000 after buying an additional 250,367 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Tarsus Pharmaceuticals by 8.0% during the second quarter. Geode Capital Management LLC now owns 934,420 shares of the company's stock worth $37,859,000 after buying an additional 68,986 shares during the last quarter. 90.01% of the stock is currently owned by institutional investors.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS stock opened at $72.93 on Monday. The company has a debt-to-equity ratio of 0.22, a current ratio of 5.26 and a quick ratio of 5.21. Tarsus Pharmaceuticals has a fifty-two week low of $35.84 and a fifty-two week high of $76.81. The stock's 50-day moving average is $58.73 and its two-hundred day moving average is $48.99. The firm has a market cap of $3.08 billion, a P/E ratio of -31.30 and a beta of 0.81.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.15). Tarsus Pharmaceuticals had a negative return on equity of 32.36% and a negative net margin of 31.13%.The firm had revenue of $102.66 million during the quarter, compared to analyst estimates of $95.81 million. Analysts predict that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current fiscal year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.